Experimental enzyme combo targets lung cancer after standard therapy fails
NCT ID NCT05616624
First seen Nov 20, 2025 · Last updated Jun 23, 2026 · Updated 29 times
Summary
This study tests a three-drug combination (ADI-PEG 20, gemcitabine, and docetaxel) in people with lung cancer that has worsened after initial treatment. The first part finds the safest dose, and the second part checks if the combination shrinks tumors. About 31 participants with non-small cell or small cell lung cancer are enrolled.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON SMALL CELL LUNG CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Inova Schar Cancer Institute
Fairfax, Virginia, 22031, United States
-
Northwestern University
Chicago, Illinois, 60611, United States
-
Washington University School of Medicine
St Louis, Missouri, 63110, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
ADI-PEG 20 (a lab-made enzyme that breaks down arginine, an amino acid cancer cells need) combined with gemcitabine and docetaxel (standard chemotherapy drugs)
What this could lead to
If it works, this could offer a new treatment option for lung cancer patients whose disease has worsened after initial therapy.
What could go wrong
This is an early-phase trial with only 31 participants, so results may not apply broadly. The combination may cause serious side effects, and it is unclear if it will improve survival.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.